# Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer

> **NCT00564720** · PHASE2 · TERMINATED · sponsor: **Hellenic Oncology Research Group** · enrollment: 140 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Gemcitabine
- **DRUG:** Erlotinib
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00564720
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 140 (ACTUAL)
- **Why stopped:** Due to poor accrual of the study
- **Last updated:** 2013-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00564720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00564720, "Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00564720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*